Gritstone Says Omicron Mutations Minimally Impact T-Cell Epitope Sequences In Its COVID-19 Vaccines


Gritstone bio Inc GRTS announced that the SARS-CoV-2 T cell epitopes (TCEs) administered within its self-amplifying mRNA (SAM) COVID-19 vaccines are minimally impacted by the Omicron (B.1.1.529) variant.

  • Gritstone says that its second-generation SARS-CoV-2 vaccine platform delivers a stabilized Spike protein and highly conserved TCEs derived from other SARS-CoV-2 viral genes, offering potentially more durable protection and broader immunity against the variants. 
  • Related Link: Gritstone Bio Secures CEPI Funding For Its Differentiated COVID-19 Vaccine Candidate.
  • Sequence analysis suggests that Omicron minimally impacts Gritstone's TCEs. 
  • Specifically, of the 146 non-Spike TCE delivered within Gritstone's vaccine currently in clinical trials in the U.K. and U.S., only 3 (~2%) are impacted by Omicron. 
  • A similar minimal impact of Omicron is observed in two new vaccine TCE constructs expected to enter clinical trials in South Africa by the end of 2021.
  • The Company expects initial clinical data from its U.K. trial in early 2022.
  • Price Action: GRTS shares are down 0.52% at $11.05 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!